Page last updated: 2024-11-13
dexamethasone phosphate(2-)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dexamethasone phosphate(2-) : A steroid phosphate oxoanion obtained by deprotonation of the phosphate OH groups of dexamethasone phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 40468194 |
| CHEBI ID | 68638 |
Synonyms (11)
| Synonym |
|---|
| dexamethasone phosphate(2-) |
| CHEBI:68638 |
| (11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl phosphate |
| NCGC00021226-03 |
| 3TC5 |
| NCGC00021226-04 |
| NCGC00021226-05 |
| bdbm235670 |
| Q27137067 |
| nsc-839137 |
| nsc839137 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| steroid phosphate oxoanion | An organophosphate oxoanion obtained by the deprotonation of one or more oxygen atoms of the phosphate group(s) of a steroid phosphoric acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 (µMol) | 4,648.7500 | 0.0058 | 2.1410 | 7.9000 | AID1803034 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 (µMol) | 4,648.7500 | 0.0002 | 1.1060 | 8.3000 | AID1803034 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Kd | 6.8000 | 6.8000 | 6.8000 | 6.8000 | AID977611 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (12)
Molecular Functions (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| arylesterase activity | Carbonic anhydrase 1 | Homo sapiens (human) |
| carbonate dehydratase activity | Carbonic anhydrase 1 | Homo sapiens (human) |
| protein binding | Carbonic anhydrase 1 | Homo sapiens (human) |
| zinc ion binding | Carbonic anhydrase 1 | Homo sapiens (human) |
| hydro-lyase activity | Carbonic anhydrase 1 | Homo sapiens (human) |
| cyanamide hydratase activity | Carbonic anhydrase 1 | Homo sapiens (human) |
| arylesterase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| carbonate dehydratase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| protein binding | Carbonic anhydrase 2 | Homo sapiens (human) |
| zinc ion binding | Carbonic anhydrase 2 | Homo sapiens (human) |
| cyanamide hydratase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (6)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Carbonic anhydrase 1 | Homo sapiens (human) |
| extracellular exosome | Carbonic anhydrase 1 | Homo sapiens (human) |
| cytoplasm | Carbonic anhydrase 2 | Homo sapiens (human) |
| cytosol | Carbonic anhydrase 2 | Homo sapiens (human) |
| plasma membrane | Carbonic anhydrase 2 | Homo sapiens (human) |
| myelin sheath | Carbonic anhydrase 2 | Homo sapiens (human) |
| apical part of cell | Carbonic anhydrase 2 | Homo sapiens (human) |
| extracellular exosome | Carbonic anhydrase 2 | Homo sapiens (human) |
| cytoplasm | Carbonic anhydrase 2 | Homo sapiens (human) |
| plasma membrane | Carbonic anhydrase 2 | Homo sapiens (human) |
| apical part of cell | Carbonic anhydrase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1803034 | CA Enzyme Assay from Article 10.3109/14756366.2011.574130: \\Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II.\\ | 2012 | Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1 | Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2011 | ACS chemical biology, Oct-21, Volume: 6, Issue:10 | Selective targeting of disease-relevant protein binding domains by O-phosphorylated natural product derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||